Document Detail


The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine.
MedLine Citation:
PMID:  15258717     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
RATIONALE: Clozapine is a unique antipsychotic, with efficacy against positive symptoms in treatment-resistant schizophrenic patients, and the ability to improve cognition and treat the negative symptoms characteristic of this disease. Despite its unique clinical actions, no specific molecular mechanism responsible for these actions has yet been described. OBJECTIVES AND METHODS: To comprehensively profile a large library of neuropsychiatric drugs, including most antipsychotics, at human monoamine receptors using R-SAT, an in vitro functional assay. RESULTS: Profiling revealed that N-desmethylclozapine (NDMC), the principal metabolite of clozapine, but not clozapine itself, is a potent and efficacious muscarinic receptor agonist, a molecular property not shared by any other antipsychotic. To further explore the role of NDMC muscarinic receptor agonist properties in mediating the physiological actions of clozapine, systemically administered NDMC was found to stimulate the phosphorylation of mitogen-activated protein kinase (MAP kinase) in mouse CA1 hippocampal neurons, an effect that was blocked by scopolamine, confirming central M1 muscarinic receptor agonist activity in vivo. Lastly, an analysis of clozapine and NDMC serum levels in schizophrenic patients indicated that high NDMC/clozapine ratios better predicted improvement in cognitive functioning and quality of life than the levels of either compound alone. CONCLUSIONS: The muscarinic receptor agonist activities of NDMC are unique among antipsychotics, and provide a possible molecular basis for the superior clinical effects of clozapine pharmacotherapy.
Authors:
D M Weiner; H Y Meltzer; I Veinbergs; E M Donohue; T A Spalding; T T Smith; N Mohell; S C Harvey; J Lameh; N Nash; K E Vanover; R Olsson; K Jayathilake; M Lee; A I Levey; U Hacksell; E S Burstein; R E Davis; M R Brann
Related Documents :
14604817 - D2s dopamine receptor mediates phospholipase d and antiproliferation.
10190227 - Prolactin and antipsychotic medications: mechanism of action.
1828707 - Cck-8 modulates d2 receptor agonist-induced hypermotility in the nucleus accumbens.
8749037 - Reversal of dizocilpine-induced disruption of prepulse inhibition of an acoustic startl...
10714237 - Regulators of growth hormone signaling.
1846357 - Tuning the responsiveness of a sensory receptor via covalent modification.
Publication Detail:
Type:  Journal Article     Date:  2004-07-16
Journal Detail:
Title:  Psychopharmacology     Volume:  177     ISSN:  0033-3158     ISO Abbreviation:  Psychopharmacology (Berl.)     Publication Date:  2004 Dec 
Date Detail:
Created Date:  2004-12-03     Completed Date:  2005-03-23     Revised Date:  2010-03-24    
Medline Journal Info:
Nlm Unique ID:  7608025     Medline TA:  Psychopharmacology (Berl)     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  207-16     Citation Subset:  IM    
Affiliation:
ACADIA Pharmaceuticals, Inc., 3911 Sorrento Valley Boulevard, San Diego, CA, USA. dweiner@acadia-pharm.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
CHO Cells
Clozapine / analogs & derivatives*,  pharmacology*
Cricetinae
Dose-Response Relationship, Drug
Hippocampus / drug effects,  physiology
Humans
Mice
Mice, Inbred C57BL
Muscarinic Agonists / pharmacology*
NIH 3T3 Cells
Receptor, Muscarinic M1 / agonists*,  physiology
Chemical
Reg. No./Substance:
0/Muscarinic Agonists; 0/Receptor, Muscarinic M1; 5786-21-0/Clozapine; 6104-71-8/norclozapine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Assessing methylphenidate preference in ADHD patients using a choice procedure.
Next Document:  Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder:...